The “Double Whammy”: Effects of erythropoiesis stimulating agents (ESAs) when administered to patients with both end stage renal disease (ESRD) and cancer.

e17623 Background: Clinical trials have identified increased risks of venous thromboembolism and mortality with ESA administration to cancer patients and increased risks of arterial thrombosis with ESA administration to ESRD patients. No empirical data has evaluated the potential association between ESA administration with severe toxicity among patients who have both ESRD and cancer. The underlying hypothesis is that these toxicities appear to...